Want to see KRMD full AI Analyst Report?
KRMD Stock Chart & Stats
$3.83
$0.25(6.53%)
At close: 4:00 PM EDT
$3.83
$0.25(6.53%)
Day’s Range― - ―
52-Week Range$3.14 - $6.61
Previous Close$4.08
Volume158.41K
Average Volume (3M)198.68K
Market Cap
$148.21M
Enterprise Value$202.96
Total Cash (Recent Filing)$8.29M
Total Debt (Recent Filing)$3.24M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,171,900
10 Day Avg. Volume166,933
30 Day Avg. Volume198,682
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)15.74
Price to Sales (P/S)6.52
P/FCF Ratio-570.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.60Price Target Upside72.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$48.04M
Bulls Say, Bears Say
Bulls Say
Recurring Installed BaseA roughly 60,000‑patient installed base and consumable-driven model create durable, repeatable revenue. Consumable reorders tied to ongoing therapy generate predictable demand, reduce customer acquisition frequency, and increase lifetime value per placement over multiple years.
Improving Cash Generation & Low LeverageOperating and free cash flow have turned positive on a TTM basis while leverage is conservative (debt/equity ~0.18). This financial flexibility supports continued commercialization, regulatory programs and strategic investments without immediate refinancing pressure, improving multi‑period resilience.
High And Improving Gross MarginsSustained high gross margins and upward guidance, aided by multiyear supplier contract and pricing gains, underpin margin durability. Stable gross margins support reinvestment in R&D and commercialization and provide a clearer path to sustained operating profitability as scale increases.
Bears Say
Ongoing Net LossesDespite margin and cash improvements, the company remains unprofitable on a TTM basis with negative ROE. Continued net losses mean equity value has yet to compound, requiring persistent margin expansion and scale to translate positive cash flow into durable shareholder returns.
Regulatory Timing RiskWithdrawing the Phesgo U.S. 510(k) delays planned oncology market entry and reduces near‑term addressable opportunity. Regulatory setbacks extend commercialization timelines, raise incremental development costs, and introduce multi‑year uncertainty into modeled revenue ramps.
Pharma Services VariabilityPharma services revenue is volatile and fell sharply year over year, reflecting timing and customer ordering patterns. Reliance on irregular clinical trial orders creates revenue lumpiness, complicates capacity planning and makes multi‑period revenue visibility less certain.
REPRO-MED Systems News
KRMD FAQ
What was REPRO-MED Systems’s price range in the past 12 months?
REPRO-MED Systems lowest stock price was $3.14 and its highest was $6.61 in the past 12 months.
What is REPRO-MED Systems’s market cap?
REPRO-MED Systems’s market cap is $148.21M.
When is REPRO-MED Systems’s upcoming earnings report date?
REPRO-MED Systems’s upcoming earnings report date is Nov 11, 2026 which is in 78 days.
How were REPRO-MED Systems’s earnings last quarter?
REPRO-MED Systems released its earnings results on Aug 05, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.018 by $0.028.
Is REPRO-MED Systems overvalued?
According to Wall Street analysts REPRO-MED Systems’s price is currently Undervalued.
Does REPRO-MED Systems pay dividends?
REPRO-MED Systems does not currently pay dividends.
What is REPRO-MED Systems’s EPS estimate?
REPRO-MED Systems’s EPS estimate is -0.02.
How many shares outstanding does REPRO-MED Systems have?
REPRO-MED Systems has 46,171,900 shares outstanding.
What happened to REPRO-MED Systems’s price movement after its last earnings report?
REPRO-MED Systems reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.018. Following the earnings report the stock price went down -13.801%.
Which hedge fund is a major shareholder of REPRO-MED Systems?
Currently, no hedge funds are holding shares in KRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
REPRO-MED Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.60 (72.32% Upside)
$6.60 (72.32% Upside)
Blogger Sentiment
Neutral
KRMD Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $49.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.58%
Trailing 12-Months
Company Description
REPRO-MED Systems
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
KRMD Company Deck
KRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful operational and financial achievements — record quarterly revenue ($12M, +18% YoY), strong domestic (+12% YoY) and international (+59% YoY) performance, margin expansion (65.1% in Q2) and return to positive net income and adjusted EBITDA — alongside strategic progress (tech acquisition, Freedom360 development, active 510(k) for deferoxamine). Offsetting items include near-term timing and execution risks: a moderated international ramp pushing some revenue into 2027, the U.S. Phesgo withdrawal delaying oncology entry, variability in pharma services (–35% YoY), and multi-year timelines for connected technology and regulatory approvals. Overall, highlights substantially outweigh the lowlights, though some growth is timing-dependent.View all KRMD earnings summariesKRMD Stock 12 Month Forecast
Average Price Target
$6.60
▲(72.32% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Utah Medical Products
―
Microbot Medical
―
―
Ownership Overview
17.42% Insiders
7.79% Mutual Funds
22.74% Other Institutional Investors
43.33% Public Companies and
Individual Investors